Cargando…
Optimal treatment of Alzheimer’s disease psychosis: challenges and solutions
Psychotic symptoms emerging in the context of neurodegeneration as a consequence of Alzheimer’s disease was recognized and documented by Alois Alzheimer himself in his description of the first reported case of the disease. Over a quarter of a century ago, in the context of attempting to develop prog...
Autores principales: | Koppel, Jeremy, Greenwald, Blaine S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247130/ https://www.ncbi.nlm.nih.gov/pubmed/25473289 http://dx.doi.org/10.2147/NDT.S60837 |
Ejemplares similares
-
Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease
por: Koppel, Jeremy, et al.
Publicado: (2016) -
Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer’s Disease Psychosis
por: Gomar, J. J., et al.
Publicado: (2022) -
Optimal nonpharmacological management of agitation in Alzheimer’s disease: challenges and solutions
por: Millán-Calenti, José Carlos, et al.
Publicado: (2016) -
Mechanism-based treatments for Alzheimer's disease
por: Davies, Peter, et al.
Publicado: (2009) -
Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)